A Review of Mathematics Determining Solute Uptake at the Blood–Brain Barrier in Normal and Pathological Conditions

Samuel A. Sprowls 1,2,†, Pushkar Saralkar 1,2,‡, Tasneem Arsiwala 1,2,*, Kathryn E. Blethen 1,2,*, Vincenzo J. Pizzuti 1,2,*, Neal Shah 2,‡, Ross Fladeland 1,2 and Paul R. Lockman 1,2,*,‡

1 Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA; sas0040@mix.wvu.edu (S.A.S.); pas0020@mix.wvu.edu (P.S.); taa0025@mix.wvu.edu (T.A.);
keblethen@mix.wvu.edu (K.E.B.); vpizzuti@mix.wvu.edu (V.J.P.); rf00015@mix.wvu.edu (R.F.)
2 Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA; nlshah@mix.wvu.edu
3 School of Pharmacy, South University, Savannah, GA 31406, USA; cadkins@southuniversity.edu
4 Department of Dermatology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA
* Correspondence: prlockman@hsc.wvu.edu; Tel.: +1-304-293-0944
† These authors contributed equally to this work.

Abstract: The blood–brain barrier (BBB) limits movement of solutes from the lumen of the brain microvascular capillary system into the parenchyma. The unidirectional transfer constant, $K_{in}$, is the rate at which transport across the BBB occurs for individual molecules. Single and multiple uptake experiments are available for the determination of $K_{in}$ for new drug candidates using both intravenous and in situ protocols. Additionally, the single uptake method can be used to determine $K_{in}$ in heterogeneous pathophysiological conditions such as stroke, brain cancers, and Alzheimer’s disease. In this review, we briefly cover the anatomy and physiology of the BBB, discuss the impact of efflux transporters on solute uptake, and provide an overview of the single-timepoint method for determination of $K_{in}$ values. Lastly, we compare preclinical $K_{in}$ experimental results with human parallels.

Keywords: pharmacokinetics; blood–brain barrier; brain; magnetic-resonance imaging; preclinical models

1. The Blood–Brain Barrier

The blood–brain barrier (BBB; Figure 1) is the tightly regulated interface of the brain and its microvascular system composed of endothelial cells (ECs), a basement membrane, pericytes, astrocytes, neurons, and microglia. Collectively, these structures cooperate as a highly selective functional barrier capable of regulating the distribution of molecules to brain parenchyma. Claudins, occludins, and junction adhesion molecules (JAMs) form an extensive paracellular barrier between ECs to small molecules, proteins and cells [1]. The ECs at the BBB also exhibit lower rates of transcytosis as a result of non-fenestrated vessels and decreased caveolin-mediated vesicle trafficking compared to the peripheral vascular system [2]. Together, pericytes and ECs secrete an extracellular matrix that surrounds the blood vessels within the brain and forms the basement membrane in which pericytes and astrocytic end-feet become embedded. Astrocytes form the outer layer of basement membrane. The basement membrane serves to facilitate essential intercellular signaling while simultaneously promoting the selective distribution of molecules into the brain parenchyma [3]. The unique characteristics of the BBB impart decreased permeability of solutes in comparison to other vascular networks throughout the periphery.

The primary functions of the BBB are to maintain homeostasis of the brain microenvironment and provide neuroprotection. The BBB preserves the brain microenvironment with influx and efflux transporters. Examples of these include the OCT1, OCT 2, LAT1, and OAT solute carrier protein transporters, which have been suggested to facilitate drug influx
at the BBB [4,5], and the P-glycoprotein efflux transporter, which minimizes the passage of many lipophilic solutes from reaching the abluminal membrane of the brain capillary network [6]. Dysregulation of the BBB affects cell signaling, immune cell trafficking, and potential neuronal damage [7]. Selective permeability of the BBB is essential for maintaining central nervous system health, but becomes an obstacle to therapeutic drug distribution into the brain to treat neurological disorders or malignancies of the CNS [8].

\[ C_{Br}(tracer/mL) = K_{in} \int_0^t C_{pl}(tracer/mL) d\tau + (V_0 + V_{pl})C_{pl} \]  

(1)

where \( C_{Br} \) (tracer/g of brain) is the concentration of tracer in brain, \( C_{pl} \) (tracer/mL) is the concentration of tracer in plasma, \( V_0 \) (mL/g) and \( V_{pl} \) (mL/g) constitute the total tracer concentrations within the brain capillary network, and \( K_{in} \) (mL/s/g) is the unidirectional transfer constant for a given solute.

To simplify the kinetic expressions and complement the data from the method above, Takasato and colleagues applied the principles above and created an in situ brain perfusion technique in which the concentration of tracer in the plasma, or in this case the perfusion buffer, remains constant. The in situ brain perfusion technique has several advantages over many traditionally applied barrier integrity protocols. The most striking difference that sets the perfusion technique apart from other methodologies is the ability of the re-
searcher to alter the buffer used to study active transport, protein binding, and a host of other interesting interactions at the BBB. Addition of increasing unlabeled substrate in combination with a constant concentration of radiolabeled substrate can provide insight to the Michaelis–Menten kinetics for a particular substrate–transporter relationship [10]. Additionally, adding serum proteins, adding known inhibitors of efflux transporters [11], or by cooling the perfusion below 37 °C provides the researchers the ability to study the effects of plasma protein binding [12], the affinity of a given substrate for a particular efflux transporter [13], and the impact of temperature [12] on nutrient transport at the BBB. Other notable advantages include avoidance of extracranial metabolism of the solute of interest, less extensive animal surgery, and the possibility to study permeability coefficients over a 10^4-fold range. The perfusion technique does not replace the intravenous injection technique, but complements the data obtained. The pharmacokinetic expression used to determine tracer uptake in the in situ brain perfusion technique is as follows in Equation (2) [14]:

\[
\frac{Q_{Br}}{C_{pf}} = K_{in} T + V_0
\]  

where \(Q_{Br}\) (tracer/g of brain) is the final concentration of solute in the brain, \(C_{pf}\) (tracer/mL) is the tracer concentration in the perfusion buffer, \(T\) (s) is perfusion time, \(V_0\) (mL/g) is the intercept of the vascular marker used in the experiment (also known as the vascular volume), and \(K_{in}\) (mL/s/g) is the unidirectional transfer constant, obtained from the regressed slope of the brain distribution volume versus time graph.

Data obtained from either of these techniques have been used to make predictive models to determine how fast a novel or understudied solute may permeate across the BBB. A handful of physiochemical properties have been determined to most notably influence BBB permeability: molecular weight, hydrogen bond donors, total polar surface area, and lipophilicity, or LogP. A good agreement exists when plotting the literature, or experimentally verified, permeability coefficients against some variation of the lipophilicity of the same solute. A variety of mathematical alterations to LogP and the use of physiochemical properties in combination with LogP have been used to form predictive estimates of uptake of a multitude of solutes. Figure 2 demonstrates the relative correlation between LogPS and Log (oil/water partition coefficient ÷ √MW). Using the slope from the linear regressed line and the physiochemical properties of a novel substrate, a theoretical or predicted permeability coefficient can be determined.

![Figure 2](image-url)
traverse the BBB. Compounds in the green-shaded area are those with values of 80% of reported cerebral blood flow or high. Compounds in the yellow shaded region indicate those with PS values between 20 and 80% of cerebral blood flow. Compounds with PS values in the red-shaded area are those with reported PS values which are less than 20% of cerebral blood flow. Values compiled from literature reported values of PS [14–17] $R^2 = 0.78$.

3. Active Efflux at the Blood–Brain Barrier

The BBB dynamically regulates homeostasis and protects the brain from exposure to endogenous entities, toxic drugs and other xenobiotic substances. Multidrug transporters present at the luminal surface of the BBB contribute towards protection by controlling drug distribution and elimination from the brain by ATP-mediated efflux. A majority of these efflux transporters belong to the ATP binding cassette (ABC) superfamily and demonstrate broad affinity for many clinically used drugs based on structure and chemistry of the molecule. Previous studies demonstrate differential expression of several types of ABC transporters at the BBB including P-glycoprotein (P-gp, MDR1, ABCB1), breast cancer resistance protein (BCRP, ABCG2), multidrug resistance protein (MRP1-6, ABCC1-6) and the organic anion transporter (OAT3) [13,18]. Amongst these, the most clinically relevant ABC transporters implicated in prohibiting drug delivery to the brain are P-gp and BCRP. These transporters are responsible for limiting brain access to a wide variety of substrates as a result of extensive expression at the BBB and blood–cerebrospinal fluid barrier (BCSFB) [19,20]. Recent studies demonstrate that these transporters have overlapping affinities for certain substrates which might lead to higher inhibitory effect to drug permeability as opposed to that observed for the individual transporters [21].

The kinetics of efflux can be determined using either of two approaches. Performing in situ brain perfusions as described above to a point of steady state, or to a point where the ratio of tracer in brain to the quantity of tracer in blood does not increase further with time, enables the use of Equation (3) [10].

$$V_{Br} = \frac{K_{in}}{K_{out}}$$ (3)

where $V_{Br}$ (mL/g) is the volume of distribution, or the ratio between tracer quantity in brain and blood, $K_{in}$ (mL/s/g) is the unidirectional transfer constant reflecting the rate at which a substance crosses the brain capillary barrier into the parenchyma, and $K_{out}$ (s$^{-1}$) is the rate of efflux of the same solute. A second way to measure the efflux constant is to use a modified in situ brain perfusion in which the brain is preloaded with the solute of interest for a nominal time, and then perfused with tracer-free perfusate for multiple durations. The brain/perfusate ratio can then plotted against time. $K_{out}$ (s$^{-1}$) can be determined from these data using the following expression in Equation (4) [10]:

$$K_{out} = \ln2/t_{1/2}$$ (4)

where $K_{out}$ (s$^{-1}$) is the rate of solute efflux from the brain capillary system, and $t_{1/2}$ is the half-life of linear regressed line on the brain/perfusate ratio versus time plot. A similar efflux constant can be determined using either expression so long as the experiments are performed correctly. The in situ brain perfusion technique is a sensitive, effective method that can be used to determine efflux kinetics as described above. Previously, the efflux of thiamine at the BBB was determined using both Equations (3) and (4) [10]. Thiamine efflux did not significantly vary between different brain regions. Interestingly, using predictive models can provide an estimate of $K_{in}$ as described above. When actual measurements of $K_{in}$ differ dramatically from predictive models, these compounds are typically subject to efflux. Additionally, in relation to Figure 2, compounds that are effluxed at the BBB typically fall below the linear regressed line indicating that something is preventing them from passing through the BBB as they should based on their physiochemical properties.
Bart et al. used the parameter of distribution volume (DV) to quantify the efflux of P-gp substrate [11C]verapamil [22,23]. The efflux of radiolabeled verapamil was measured in rats using PET, and Logan analysis technique was used to calculate the DV. Logan analysis measures the radioactivity of the analyte drug in the region of interest, and the DV is calculated as the slope of the Logan plot. MRI imaging has been used to determine the efflux kinetics after focused ultrasound induced BBB opening. The efflux was found to drop in the FUS-exposed regions, and slowly recovered in a time dependent manner [22].

4. Flow- vs. Perfusion-Limited Blood–Brain Barrier Transport

Simple diffusion of compounds across the BBB occurs either paracellularly (between the cells), or transcellularly (through the endothelial cells) [2,24]. Hydrophilic compounds frequently rely on paracellular diffusion due to their poor ability to penetrate the lipid bilayer of the endothelial cell membrane. However, the presence of tight junctions between ECs greatly limits this process. For a compound to cross into the brain transcellularly, it requires an optimal balance between lipophilicity and hydrophilicity to cross the lipid bilayers of the cells as well as the aqueous cytosol. The Lipinski’s ‘Rule of 5’ assists in the prediction of a compound’s BBB permeability. According to this general rule, compounds with fewer than 5 H-bond donors, fewer than 10 H-bond acceptors, a molecular weight less than 500 daltons, and a calculated partition coefficient (logP) value less than 5 are good candidates for BBB permeability [15,25,26]. The logP, determined as the octanol-water partition coefficient of a molecule, denotes its lipophilicity. Generally, a direct relation exists between the passive permeability of a compound across the BBB, and its logP value [27]. This proportionality may not hold true in the case of hydrophilic compounds that undergo transport through specific channels, or lipophilic compounds that are subject to active efflux. Compounds with high lipid solubility can traverse the BBB via simple diffusion process; their entry into the brain is less limited by their physicochemical properties, or carrier-based transport. As a result, the limiting step for the entry of these molecules into the brain is the velocity at which they are supplied to the BBB interface by the blood. Such compounds are said to have a flow-limited BBB permeability. Examples of these compounds include ethanol and diazepam. Of note, these flow-limited compounds are typically used as a measure of cerebral blood flow. Conversely, as a compound’s logP decreases or becomes more negative, its lipid partitioning decreases and, therefore, exhibits a reduction in passive BBB permeability. Their entry into the brain tissue is not dependent on blood flow, and instead depends on their permeability across the BBB, which is indirectly dictated by their physicochemical properties. Such compounds are said to have a permeability limited BBB transport. The transport of solutes occurs over the entire area of the capillary network, and thus to take the surface area into account, the product of permeability and surface area is often used to describe the measure of solute exchange across the BBB, instead of the permeability coefficient alone [27]. Assuming a unidirectional diffusion of solute, the concentration of solute extracted from blood flowing through brain capillaries correlates with the permeability surface area product using the Renkin–Crone equation as follows (Equation (5)):

\[ E = 1 - e^{-PA/F} \]  

(5)

where \( E \) is the total solute extraction from blood, \( P \) is the solute permeability (cm/s), \( A \) is the total capillary surface area (cm²/g of brain), and \( F \) is the total blood flow (cm³/s/g of brain). The above equation can be rearranged solving for the permeability surface area product, \( PA \) (Equation (6)):

\[ PA = -F \ln(1 - E) \]  

(6)

The unidirectional transfer coefficient, \( K_{in} \) (cm/s/g) can be represented as the product of solute extraction and blood flow (Equation (7)):

\[ K_{in} = F \times E \]  

(7)
when the PA values are high ($PA/F > 1$), and $K_{in}$ approaches $F$, solute entry is blood flow limited. When the PA values are low ($PA/F < 1$), and $K_{in}$ approaches the permeability surface area product, solute extraction from blood is independent of blood flow and is considered diffusion limited, as depicted in Figure 3 [28–31]. The values of $PA$ can range between $10^{-4}$ and $10^{-5}$ cm/s. Higher $PA$ values of $10^{-5}$ to $10^{-4}$ cm/s are observed for solutes with a flow-limited transport such as ethanol, caffeine, antipsychotic drugs, and many CNS depressants. Diffusion limited hydrophilic solutes, such as sucrose and mannitol, exhibit PA values several orders of magnitude less, frequently in the ranges of $10^{-7}$ and $10^{-8}$ cm/s [32].

![Figure 3. A schematic representation of (A) extraction-limited and (B) flow-limited solute transfer across the BBB. The physicochemical properties of compounds having extraction-limited permeability are not amenable to BBB transport. Conversely, the transport of highly permeable solutes across the BBB is generally quick, and only limited by how rapidly they are presented to the BBB.](image)

5. Preclinical Measurements of Blood–Brain Barrier Permeability in Pathological Conditions

Historically, measurements of BBB permeability have been achieved through multiple methodologies. These approaches include the indicator-diffusion, the brain uptake index, the concentration profile analysis, the isolated perfused brain, the intravenous injection, the in situ brain perfusion, and the multiple-time uptake techniques [13,14,31,33–38]. Each of these methodologies presents its own limitations ranging from inappropriate assumptions regarding tracer and blood mixing, to inaccurate estimations of poorly or rapidly penetrating solutes, and extensive animal surgery [14]. The in situ brain perfusion is capable of estimating transfer coefficients and evaluating barrier integrity with high fidelity [14,16,28,39–42]. However, this technique presents limitations regarding its ability to yield reproducible results in disease states with a heterogeneous disruption of the BBB (i.e., brain tumors, stroke, Alzheimer’s disease, etc.). To ascertain these subtle, variable changes in BBB integrity, the single-uptake approach is widely recognized as the preferred methodology [38,43].

The unidirectional transfer constant, $K_{in}$, in single-uptake experiments following an intravenous injection of the solute of interest is defined by the relationship in Equation (8) [9,44–46]:

$$K_{in} = \frac{C_{br}(\tau)}{\int_0^T C_{bl}(\tau) \, dt}$$  

where $C_{br}$ is the concentration of tracer contained in the brain compartment of interest at time $T$, and $C_{bl}$ is the concentration of solute in blood. The denominator of this expression solves for the area under the curve of the change in plasma concentration from time 0 to time $T$ and indicates total exposure to the solute through the duration of the experiment.
The integral of the plasma concentration versus time curve is necessary because the concentration of the test solute in blood changes over time as a result of metabolism and clearance of the tracer. $C_{br}$ is the total concentration of measurable solute that has left the vascular compartment and distributes to the brain compartment, which is also expressed as the total quantity in brain as follows (Equation (9)):

$$C_{tot} = C_{br} + C_{vas}$$  \hspace{1cm} (9)$$

where $C_{tot}$ is the total concentration of solute in the brain vascular compartments, and $C_{vas}$ is the concentration of solute in the vascular space within the brain. Subtraction of the measured $C_{vas}$ from $C_{tot}$ provides a reliable estimate of $C_{br}$, or the quantity of tracer distribution into brain for a given period of circulation time and unit of tissue mass.

While the pharmacokinetic evaluations in this review provide an estimate of the unidirectional transfer constant for a solute, it has limited insight into the amount of unbound drug in both the blood and brain at a specific time. When considering pharmacokinetics of a solute’s transport from blood to brain it is important to understand that only unbound solute can permeate across the BBB, and the unbound concentration of solute is what drives pharmacodynamic activities [47]. To determine this, an equilibrium micro-dialysis method is used, where a semi-permeable probe is inserted into a specific brain region and perfusate is flowed through an interior probe and allowed to passively diffuse across the outer semipermeable membrane. The dialysate is then measured by collection from the outlet tube [48,49]. Briefly the equilibrium constant $K_{p,uu}$ (unbound partition coefficient) is determined as follows in Equation (10):

$$K_{p,uu} = \frac{AUC_{u,brain} \text{ISF}}{AUC_{u,plasma}}$$  \hspace{1cm} (10)$$

where $AUC_{u,brain}$ and $AUC_{u,plasma}$ represents the total exposure of unbound drug in brain and plasma, respectively [49,50]. Determining $K_{p,uu}$ provides information on the concentration of drug freely able to act within the brain parenchyma. This measure accounts for tissue binding affinity and the properties of active and passive transport across the BBB [51], though it does not directly measure BBB transport constants. Values of $K_{p,uu}$ are reported to range from as low as 0.02 and 3. Contextually, solutes with high BBB permeability/equilibrium such as diazepam and oxycodone have a $K_{p,uu}$ value of 1 and 3, respectively [52,53]. Conversely, baclofen and morphine, solutes with poor BBB penetration and equilibrium, have a reported $K_{p,uu}$ values of 0.02 and 0.29 respetively [54,55].

6. Clinical BBB PK in Disease States and Preclinical Model Translatability

Measurement of BBB permeability and disruption in humans is not as direct as preclinical models but is readily achieved with advanced imaging techniques such as dynamic contrast-enhanced MRI (DCE-MRI), often employed in oncology and stroke imaging studies [56–59]. This type of imaging provides researchers and clinicians with estimates of $K_{trans}$ to quantify BBB permeability. As defined by Tofts, $K_{trans}$, with units of min$^{-1}$ (or time$^{-1}$), is a volume transfer constant between blood plasma and extravascular, extracellular space, predominantly intended for use with tracers that do not readily enter intracellular compartments (i.e., non-lipophilic tracers) [60]. Measures of $K_{trans}$ in DCE-MRI studies are often calculated utilizing the extended Tofts-Kety (ETK) model, but can also be estimated from linearized Patlak plots of concentration versus time data; however, this method assumes negligible backflow of contrast agent from extravascular spaces into blood vessels during the scanning period [60–63]. Unlike $K_{in}$ values, $K_{trans}$ is expressed in units of time$^{-1}$ because each concentration term is based solely on volumetric signal and cannot be normalized to brain tissue mass, as is the case for preclinical determinations.
of $K_{\text{in}}$. The ETK and linearized Patlak model equations frequently used in this setting are displayed below (Equations (11) and (12)) [60,61,64]:

$$C_{\text{br}}(t) = K_{\text{trans}} \int_0^t C_{\text{br}}(\tau)e^{-k_{\text{el}}(t-\tau)}d\tau + f_{\text{vasc}}C_{\text{bl}}(t)$$ (ETK Model) \hspace{1cm} (11)

$$C_{\text{br}}(t) = K_{\text{trans}} \int_0^t C_{\text{br}}(\tau)d\tau + f_{\text{vasc}}C_{\text{bl}}(t)$$ (Linearized Patlak Model) \hspace{1cm} (12)

where $C_{\text{br}}$ is the concentration of contrast agent in the brain compartment, $C_{\text{bl}}$ is concentration in the blood, $f_{\text{vasc}}$ is the volume fraction of vasculature in the tissue, and $k_{\text{el}}$ is the elimination rate constant from brain to blood compartments. In the linearized Patlak model, the elimination rate constant is ignored as discussed previously. After pre- and post-contrast infusion scans are obtained, non-linear (ETK) and linear (Patlak) least squares regression of these parametric equations are used to estimate $K_{\text{trans}}$. The estimates of permeability changes or barrier disruption provide important clinical implications regarding many disease states, including cancer and stroke.

Brain tumors, whether primary or metastatic, heterogeneously disrupt local brain microvascular architecture and function which results in variable increases to passive permeability of the blood–tumor barrier (BTB) [65,66]. Notably, measures of $K_{\text{trans}}$ in human gliomas are often elevated by orders of magnitude compared to healthy contralateral brain tissue and has been shown to correlate with glioma grade [61,67]. Trends in permeability increases, indicated by fold-changes in $K_{\text{in}}$, values for lesioned versus normal brain are also observed in mouse models of glioma and breast cancer brain metastasis [38,68,69]. Agreement in trends between the estimates of fold-enhancement indicates that these mouse models faithfully capture the important underlying factors that dictate BBB permeability changes observed in humans.

In the case of acute ischemic stroke, clinical studies employing DCE-MRI have found significant increases in the value of $K_{\text{trans}}$ in affected regions compared to normal contralateral areas of brain parenchyma [70]. Elevated fold changes in $K_{\text{trans}}$ between affected and unaffected regions (in one study, approximately 3.5 for early post-stroke and approximately 23 for 5–7 day follow-up) [70] are similar in magnitude to the changes in relative permeability of the BBB to dye observed in a rat model of ischemic stroke (approximately 15 fold change) [71]. This indicates that BBB permeability measurements in rodent stroke models effectively mimic the types of changes in permeability between stroke-affected and unaffected brain regions in human.

Previously discussed disease states provide validation and justification for the continued use of mouse and rat models due to their observed pathophysiological mimicry to clinically observed BBB function in these disease settings. While absolute values observed in these preclinical models do not scale directly to clinical values, the observed fold-changes in BBB permeability appear to translate consistently. Preclinical experiments studying BBB permeability across various diseases should be designed in light of the importance of appropriate normal parenchymal controls, as such measures set the baseline for determination of clinically translatable and meaningful fold-change measurements.

Interestingly, the magnitude of fold-change is notably different among preclinical and clinical determinations of passive permeability. One proposed source of variance that may be distinct other than the mathematics applied to each model is the tracer used in each study. Tracer or particle charge, size, polar surface area, among other properties, all variably affect BBB transport. Keeping in mind these parameters, a difference in fold-change of 9.2 for TxRed and 47.7 for Gd-DPTA both in a glioma model may not be all that different given the difference in physiology of mice and humans, as well as the immune system status in various animal models. Both provide measures of barrier damage, but also are indicative of the size, charge, and other chemical properties of that molecule. Figure 4 shows the difference in uptake of three distinct solutes detected through three separate imaging modalities. The BBB is consistent from species to species, at least in the case of humans and small rodents regarding cellular makeup and the rate of uptake of
solutes at the BBB. However, what does change among specifics is the specific transporter composition (i.e., BCRP, P-gp, MRP1, etc.) at the BBB. While these data may indicate differences among methods, other correlates of animal and human data can be provided regarding therapeutic efficacy and brain tumors.

Figure 4. Differential tracer uptake in various imaging modalities. Accumulation of Texas Red 3K (A) and 14C-aminoisobutyric acid (B) in brain metastases of breast cancer using fluorescent and phosphorescent quantitative imaging. (C)T1 cortical Turbo Spin Echo MRI indicating gadavist enhancement in lesions within the brain.

7. Conclusions

The BBB dictates the kinetics of solute transfer into and out of the brain, having implications over the extent of drug distribution and treatment efficacy. This review outlines the techniques and the mathematical models commonly used to determine solute influx and efflux across the BBB. These techniques, such as in situ perfusion and Patlak modeling have found application in preclinical as well as clinical research. Determination of the rate of drug transfer across the BBB bears great significance during the preclinical and early stage CNS drug development process. Application of such methods could help predict drug disposition, allowing for optimal treatment of CNS pathologies. Furthermore, this review is limited in its capacity, largely describing the unidirectional transfer rate at which a particular solute crosses the BBB. Not described herein are other sophisticated methods that also aim to determine BBB transport such as the use of microdialysis and serial CSF sampling. A complex multimodal approach using a variety of uptake methodology would be suitable for a more complete understanding of BBB transport for any given solute.

Author Contributions: Conceptualization, comprehensive writing, reviewing, figure generation, and manuscript preparation, S.A.S., P.S. and P.R.L. Writing and review, T.A., K.E.B., V.J.P. and R.F. Writing, review, and figure generation, C.E.A. and N.S. Funding acquisition S.A.S. and P.R.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by National Cancer Institute, grant number F99CA253768-01, and by the National Institute of General Medical Sciences, grant number 5P20GM121322-03 and 5P20GM121322-03S1. Additional funding was also provided by the Mylan Chair Endowment Fund and METAvivor.

Data Availability Statement: All figures and data can be obtained by contacting the corresponding author, Paul R. Lockman.

Acknowledgments: We would like to acknowledge Peng Wang and Olivia Wilson of the WVU Rockefeller Neuroscience Institute for their work providing MRI imaging assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Daneman, R.; Prat, A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 2015, 7, a020412. [CrossRef]
2. Abbott, N.J.; Patabendige, A.; Dolman, D.E.; Yusof, S.R.; Begley, D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37, 13–25. [CrossRef]
3. Xu, L.; Nirwane, A.; Yao, Y. Basement membrane and blood–brain barrier. Stroke Vasc. Neurol. 2019, 4, 78–82. [CrossRef]
4. Kalliokoski, A.; Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 2009, 158, 693–705. [CrossRef]
5. Nakanishi, T.; Tamai, I. Solute Carrier Transporters as Targets for Drug Delivery and Pharmacological Intervention for Chemotherapy. *J. Pharm. Sci.* 2011, 100, 3731–3750. [CrossRef]

6. Mergenthaler, P.; Lindau, U.; Dienel, G.A.; Meisel, A. Sugar for the brain: The role of glucose in physiological and pathological brain function. *Trends Neurosci.* 2013, 36, 587–597. [CrossRef]

7. Zhao, Z.; Nelson, A.R.; Betsholtz, C.; Zlokovic, B.V. Establishment and Dysfunction of the Blood-Brain Barrier. *Cell* 2015, 163, 1064–1078. [CrossRef]

8. Sprowls, S.A.; Arsiwala, T.A.; Bumgarner, J.R.; Shah, N.; Lateef, S.S.; Kielkowsk, B.N.; Lockman, P.R. Improving CNS Delivery to Brain Metastases by Blood–Tumor Barrier Disruption. *Trends Cancer* 2019, 5, 495–505. [CrossRef]

9. Patlak, C.S.; Blasberg, R.G.; Fenstermacher, J.D. Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data. *Br. J. Pharmacol.* 1983, 3, 1–7. [CrossRef]

10. Lockman, P.R.; Mumper, R.J.; Allen, D.D. Evaluation of blood-brain barrier thiamine efflux using the in situ rat brain perfusion method. *J. Neurochem.* 2003, 86, 627–634. [CrossRef]

11. Manda, V.K.; Mittapalli, R.K.; Bohn, K.A.; Adkins, C.E.; Lockman, P.R. Nicotine and cotinine increases the brain penetration of saquinavir in rat. *J. Neurochem.* 2010, 115, 1495–1507. [CrossRef] [PubMed]

12. Thomas, F.C.; Taskar, K.; Rudraraju, V.; Goda, S.; Thorshelm, H.R.; Gaasch, J.A.; Mittapalli, R.K.; Palmieri, D.; Steeg, P.S.; Lockman, P.R.; et al. Uptake of ANGI005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. *Pharm. Res.* 2009, 26, 2486–2494. [CrossRef] [PubMed]

13. Adkins, C.E.; Mittapalli, R.K.; Manda, V.K.; Nounou, M.I.; Mohammad, A.S.; Terrell, T.B.; Bohn, K.A.; Yasemin, C.; Grothe, T.R.; Lockman, J.A.; et al. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. *Front. Pharmacol.* 2013, 4, 136. [CrossRef]

14. Takasato, Y.; Rapoport, S.I.; Smith, Q.R. An in situ brain perfusion technique for study cerebrovascular transport in the rat. *Am. J. Physiol. Circ. Physiol.* 1984, 247, H184–H193. [CrossRef]

15. Geldenhuys, W.J.; Mohammad, A.S.; Adkins, C.E.; Lockman, P.R. Molecular determinants of blood–brain barrier permeation. *Ther. Deliv.* 2015, 6, 961–971. [CrossRef]

16. Smith, Q.R.; Allen, D.D. In situ brain perfusion technique. *Methods Mol. Med.* 2003, 89, 209–218. [CrossRef]

17. Smith, Q.R. A Review of Blood–Brain Barrier Transport Techniques. *Blood Brain Barrier 2003*, 89, 193–208. [CrossRef]

18. Löscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. *NeuroRx* 2005, 2, 86–98. [CrossRef]

19. De Lange, E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. *Adv. Drug Deliv. Rev.* 2004, 56, 1793–1809. [CrossRef]

20. Ohtsuki, S.; Uchida, Y.; Kubo, Y.; Terasaki, T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: Methodology, advantages, strategy, and prospects. *J. Pharm. Sci.* 2011, 100, 3547–3559. [CrossRef]

21. Agarwal, S.; Hartz, A.M.; Elmqvist, W.F.; Bauer, B. Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up. *Curr. Pharm. Des.* 2011, 17, 2793–2802. [CrossRef] [PubMed]

22. Chai, W.Y.; Chu, P.C.; Tsai, M.Y.; Lin, Y.C.; Wang, J.J.; Wei, K.C.; Wai, Y.Y.; Liu, H.L. Magnetic-resonance imaging for kinetic assessment of P-glycoprotein function in the rat blood–brain barrier by distribution volume of [11C]verapamil measured with PET. *NeuroImage* 2003, 20, 1775–182. [CrossRef]

23. Preston, J.E.; Abbott, N.J.; Begley, D.J. Transcytosis of Macromolecules at the Blood–Brain Barrier. *Adv. Drug Deliv. Rev.* 2014, 71, 147–163. [PubMed]

24. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational methods to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* 2001, 46, 3–26. [CrossRef] [PubMed]

25. Vendel, E.; Rottschäfer, V.; de Lange, E.C.M. The need for mathematical modelling of spatial drug distribution within the brain. *Fluids Barriers CNS* 2019, 16, 12. [CrossRef] [PubMed]

26. Bradbury, M.W. The blood-brain barrier. Transport across the cerebral endothelium. *Circ. Res.* 1985, 57, 213–222. [CrossRef]

27. Smith, Q.R.; Takasato, Y. Kinetics of Amino Acid Transport at the Blood–Brain Barrier Studied Using an in Situ Brain Perfusion Technique. *Ann. N. Y. Acad. Sci.* 1986, 481, 186–201. [CrossRef]

28. Robinson, P.J. Measurement of Blood-Brain Barrier Permeability. *Clin. Exp. Pharmacol. Physiol.* 1990, 17, 829–840. [CrossRef]

29. Partridge, W.M. CSF, blood-brain barrier, and brain drug delivery. *Expert Opin. Drug Deliv.* 2016, 13, 963–975. [CrossRef]

30. Jain, R.; Ellika, S.; Scarpace, I.; Schultz, L.; Rock, J.; Gutierrez, J.; Patel, S.; Ewing, J.; Mikkelson, T. Quantitative Estimation of Permeability Surface-Area Product in Astroglial Brain Tumors Using Perfusion CT and Correlation with Histopathologic Grade. *Am. J. Neuroradiol.* 2008, 29, 694–700. [CrossRef] [PubMed]

31. Wong, A.D.; Ye, M.; Levy, A.F.; Rothstein, J.D.; Bergles, D.E.; Searson, P.C. The blood-brain barrier: An engineering perspective. *Front. Neuropath.* 2013, 6, 7. [CrossRef]

32. Oldendorf, W.H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. *Am. J. Physiol. Content* 1971, 221, 1629–1639. [CrossRef]
34. Patlak, C.S.; Fenstermacher, J.D. Measurements of dog blood–brain transfer constants by ventriculocisternal perfusion. Am. J. Physiol. Content 1975, 229, 877–884. [CrossRef] [PubMed]
35. Raichle, M.E.; Eichling, J.O.; Straatmann, M.G.; Welch, M.J.; Larson, K.B.; Ter-Pogossian, M.M. Blood–brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. Am. J. Physiol. Content 1976, 230, 543–552. [CrossRef]
36. Crane, C. The Permeability of Capillaries in Various Organs as Determined by the Use of the ‘Indicator Diffusion’ Method. Acta Physiol. Scand. 1963, 58, 292–305. [CrossRef]
37. Ohno, K.; Pettigrew, K.D.; Rapoport, S.I. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. Circ. Physiol. 1978, 235, H299–H307. [CrossRef]
38. Mittapalli, R.K.; Manda, V.K.; Bohn, K.A.; Adkins, C.E.; Lockman, P.R. Quantitative fluorescence microscopy provides high resolution imaging of passive diffusion and P-gp mediated efflux at the in vivo blood–brain barrier. J. Neurosci. Methods 2013, 219, 188–195. [CrossRef] [PubMed]
39. Allen, D.D.; Smith, Q.R. Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 2001, 76, 1032–1041. [CrossRef]
40. Smith, Q.R.; Takasato, Y.; Sweeney, D.J.; Rapoport, S.I. Regional Cerebrovascular Transport of Leucine as Measured by the in situ Brain Perfusion Technique. Br. J. Pharmacol. 1985, 5, 300–311. [CrossRef]
41. Lockman, P.R.; McAfee, G.; Sweeney, D.J.; Rapoport, S.I. Regional Cerebrovascular Transport of Leucine as Measured by the in situ Brain Perfusion Technique. Br. J. Pharmacol. 1985, 5, 300–311. [CrossRef]
42. Lockman, P.R.; Manda, V.K.; Goldenhuyys, W.J.; van der Schyf, C.J.; Abbruscato, T.J.; Allen, D.D. Brain Uptake Kinetics of Nicotine and Cotine after Chronic Nicotine Exposure. J. Pharmacol. Exp. Ther. 2005, 314, 636–642. [CrossRef] [PubMed]
43. Lockman, P.R.; Manda, V.K.; Goldenhuyys, W.J.; Mittapalli, R.K.; Thomas, F.; Albayati, Z.F.; Crooks, P.A.; Dwoskin, L.P.; Allen, D.D. Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N′-Dodecylbispicolinium Dipromide at the Blood–Brain Barrier. J. Pharmacol. Exp. Ther. 2007, 324, 244–250. [CrossRef] [PubMed]
44. Asotra, K.; Ningaraj, N.; Black, K.L. Measurement of Blood–Brain and Blood–Tumor Barrier Permeabilities with [14C]-Labeled Tracers. Blood Brain Barrier 2003, 89, 177–190.
45. Nakagawa, H.; Grothhaus, D.K.; Owens, E.S.; Fenstermacher, J.D.; Patlak, C.S.; Blasberg, R.G. Dexamethasone Effects on [125I]Albumin Distribution in Experimental RG-2 Gliomas and Adjacent Brain. Br. J. Pharmacol. 1987, 7, 687–701. [CrossRef]
46. Blasberg, R.G.; Shapiro, W.R.; Molnar, P.; Patlak, C.S.; Fenstermacher, J.D. Local blood flow in Walker 256 metastatic brain tumors. J. Neuro Oncol. 1984, 2, 195–204. [CrossRef]
47. Blasberg, R.G.; Fenstermacher, J.D.; Patlak, C.S. Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J. Cereb. Blood Flow Metab. 1992, 3, 8–32. [CrossRef]
48. Loryan, I.; Hammular Lund- Udenaes, M.; Syvännø, S. Brain Distribution of Drugs: Pharmacokinetic Considerations. In Handbook of Experimental Pharmacology; Springer: Berlin/Heidelberg, Germany, 2020.
49. Hammular Lund- Udenaes, M. Microdialysis as an Important Technique in Systems Pharmacology—a Historical and Methodological Review. AAPS J. 2017, 19, 1294–1303. [CrossRef]
50. Gupta, A.; Chatelain, P.; Massingham, R.; Jonsson, E.N.; Hammular Lund- Udenaes, M. Brain distribution of cetirizine enantiomers: Comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metab. Dispos. 2006, 34, 318–323. [CrossRef]
51. Hu, Y.; Gaillard, P.J.; Rip, J.; de Lange, E.C.; Hammular Lund- Udenaes, M. In Vivo Quantitative Understanding of PE Gylated Liposome’s Influence on Brain Delivery of Diphenhydramine. Mol. Pharm. 2018, 15, 5493–5500. [CrossRef]
52. Hammular Lund- Udenaes, M.; Fridén, M.; Syvännø, S.; Gupta, A. On The Rate and Extent of Drug Delivery to the Brain. Pharmn. Res. 2007, 25, 1737–1750. [CrossRef]
53. Boström, E.; Simonsson, U.S.H.; Hammular Lund- Udenaes, M. In Vivo Blood–Brain Barrier Transport of Oxycodone in the Rat: Indications for Active Influx and Implications for Pharmacokinetics/Pharmacodynamics. Drug Metab. Dispos. 2006, 34, 1624–1631. [CrossRef] [PubMed]
54. Dube, R.K.; McAllister, C.B.; Inoue, M.; Wilkinson, G.R. Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. J. Clin. Investitig. 1989, 84, 1155–1159. [CrossRef] [PubMed]
55. Deguchi, Y.; Inabe, K.; Tomiyasu, K.; Nosawa, K.; Yamada, S.; Kimura, R. Study on brain interstitial fluid distribution and blood-brain barrier transport of clofazin in rats by microdialysis. Pharmn. Res. 1995, 12, 1838–1844. [CrossRef] [PubMed]
56. Tunblad, K.; Jonsson, E.N.; Hammular Lund- Udenaes, M. Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharmn. Res. 2003, 20, 618–623. [CrossRef]
57. Yankeeov, T.E.; Gore, J.C. Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. Curr. Med. Imaging Rev. 2009, 3, 91–107. [CrossRef]
58. Mross, K.; Fasol, U.; Frost, A.; Benkelmann, R.; Kuhlmann, J.; Büchert, M.; Unger, C.; Blum, H.; Hennig, J.; Milenkova, T.P.; et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: A randomized phase I study. J. Angiogenesis Res. 2009, 1, 5. [CrossRef] [PubMed]
59. Leigh, R.; Jen, S.S.; Hills, A.E.; Krakauer, J.W.; Barker, P.B.; Albers, G.W.; Davis, S.M.; Donnan, G.A.; Fisher, M.; Furlan, A.J.; et al. Pretreatment Blood–Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. Stroke 2014, 45, 2030–2035. [CrossRef] [PubMed]
60. Gordon, Y.; Partovi, S.; Müller-Eschner, M.; Amarteifio, E.; Bäuerle, T.; Weber, M.-A.; Kauczor, H.-U.; Rengier, F. Dynamic contrast-enhanced magnetic resonance imaging: Fundamentals and application to the evaluation of the peripheral perfusion. Cardiovasc. Diagn. Ther. 2014, 4, 147–164.
60. Tofts, P.S.; Brix, G.; Buckley, D.L.; Evelhoch, J.L.; Henderson, E.; Knopp, M.V.; Larsson, H.B.; Lee, T.-Y.; Mayr, N.A.; Parker, G.J.; et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer. Standardized quantities and symbols. *J. Magn. Reson. Imaging* 1999, 10, 223–232. [CrossRef]

61. Bergamino, M.; Saitta, L.; Barletta, L.; Bonzano, L.; Mancardi, G.L.; Castellan, L.; Ravetti, J.L.; Roccatagliata, L. Measurement of Blood-Brain Barrier Permeability with T1-Weighted Dynamic Contrast-Enhanced MRI in Brain Tumors: A Comparative Study with Two Different Algorithms. *ISRN Neurosci.* 2013, 2013, 905279. [CrossRef]

62. Tofts, P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. *J. Magn. Reson. Imaging* 1997, 7, 91–101. [CrossRef] [PubMed]

63. Zhang, N.; Zhang, L.; Qi, B.; Meng, L.; Wang, X.; Hou, B.L. Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas. *J. Magn. Reson. Imaging* 2012, 36, 355–363. [CrossRef] [PubMed]

64. Law, M.; Yang, S.; Babb, J.S.; Knopp, E.A.; Gofinios, J.G.; Zagzag, D.; Johnson, G. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. *Am. J. Neuroradiol.* 2004, 25, 746–755. [PubMed]

65. Gerstner, E.R.; Fine, R.L. Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm. *J. Clin. Oncol.* 2007, 25, 2306–2312. [CrossRef] [PubMed]

66. De Vries, N.A.; Beijnen, J.H.; Boogerd, W.; van Tellingen, O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. *Expert Rev. Neurother.* 2006, 6, 1199–1209.

67. Zhang, J.; Liu, Z.; Du, X.; Guo, Y.; Chen, X.; Wang, S.; Fang, J.; Cao, P.; Zhang, B.; Zhang, W. Increasing of Blood-Brain Tumor Barrier Permeability through Transcellular and Paracellular Pathways by Microbubble-Enhanced Diagnostic Ultrasound in a C6 Glioma Model. *Front. Neurosci.* 2017, 11, 86. [CrossRef] [PubMed]

68. Lockman, P.R.; Mittapalli, R.K.; Taskar, K.S.; Rudraraju, V.; Gril, B.; Bohn, K.A.; Adkins, C.E.; Roberts, A.; Thorsheim, H.R.; Gaasch, J.A.; et al. Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer. *Clin. Cancer Res.* 2010, 16, 5664–5678. [CrossRef]

69. Mohammad, A.S.; Adkins, C.E.; Shah, N.; Aljamal, R.; Griffith, J.I.G.; Tallman, R.M.; Jarrell, K.L.; Lockman, P.R. Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer. *BMC Cancer* 2018, 18, 1225. [CrossRef]

70. Villringer, K.; Cuesta, B.E.S.; Ostwaldt, A.-C.; Grittner, U.; Khalil, A.A.; Schindler, K.; Eisenblätter, O.; Audebert, H.; Fiebach, J.B. DCE-MRI blood–brain barrier assessment in acute ischemic stroke. *Neurology* 2016, 88, 433–440. [CrossRef]

71. Fernández-López, D.; Faustino, J.; Daneman, R.; Zhou, L.; Lee, S.Y.; Derugin, N.; Wendland, M.F.; Vexler, Z.S. Blood-Brain Barrier Permeability is Increased After Acute Adult Stroke But Not Neonatal Stroke in the Rat. *J. Neurosci.* 2012, 32, 9588–9600. [CrossRef]